Anthem Biosciences IPO: The three-day subscription for the initial public offering (IPO) of Anthem Biosciences Limited will open on July 14, Monday. The Anthem Biosciences IPO subscription will close on July 16 (Wednesday).
As per the circular, the company has allocated 1.78 crore equity shares to 60 funds at Rs 570 apiece, which is the upper end of the price band. This aggregates the transaction size to Rs 1,016 crore, reports PTI.
Anthem Biosciences IPO Anchor Investors
Anthem Biosciences has raised Rs 1,016 crore from anchor investors ahead of its initial share-sale opening for public subscription. Some of the investors that participated in the anchor book are — Abu Dhabi Investment Authority, Government Pension Fund Global, Eastspring Investments, Amundi Funds, PineBridge Global Funds and Societe Generale, HDFC MF (MF), ICICI Prudential MF, Axis MF, UTI MF, Quant MF and Motilal Oswal MF, according to BSE.
Anthem Biosciences IPO Price Band
Anthem Biosciences IPO has fixed the price band at Rs 540 to Rs 570 per equity share.
Anthem Biosciences IPO Registrar
KFin Technologies Limited is the registrar of Anthem Biosciences IPO.
Anthem Biosciences IPO Face Value, Tick Size
The face value and tick size of Anthem Biosciences IPO is Rs 2 and Re 1, respectively.
Anthem Biosciences IPO Allotment Date
According to the details available, the Anthem Biosciences IPO will be July 17.
Story continues below this ad
Anthem Biosciences IPO Listing Date
Anthem Biosciences Limited’s shares are proposed to be listed on NSE, and BSE. The listing will likely take place on July 21.
Anthem Biosciences IPO Book Running Lead Managers
JM Financial Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited and Nomura Financial Advisory and Securities (India) Private Limited are the book running lead managers for the Anthem Biosciences IPO.
Anthem Biosciences IPO Sponsor Bank
HDFC Bank Limited and ICICI Bank Limited are the sponsor banks for the Anthem Biosciences IPO.
About Anthem Biosciences Limited
Anthem is into innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing.
Story continues below this ad
It also manufactures and sells complex specialized fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars.
(With inputs from PTI)
© IE Online Media Services Pvt Ltd
